VIP Peptide Protects the Gut from Radiation Damage by Boosting Intestinal Stem Cell Regeneration | Research

The takeaway

Vasoactive intestinal peptide (VIP) promotes gut stem cell regeneration and significantly reduces radiation-induced intestinal injury in mice.

VIP mitigated 12 Gy radiation injury in vivo
Mice receiving VIP injections after abdominal irradiation showed significantly reduced intestinal damage, with VIP promoting stem cell-driven regeneration through the p38 MAPK pathway.

What the researchers found

Vasoactive intestinal peptide (VIP) protects the gut from radiation damage by promoting intestinal stem cell differentiation and regeneration. VIP drove intestinal epithelial cells toward a secretory phenotype primarily through the p38 MAPK signaling pathway and modulated the proliferation of Lgr5+ progenitor cells (intestinal stem cells). After radiation injury, these stem cells became more responsive to VIP's effects, and VIP strongly promoted epithelial regeneration. Critically, these findings held in live mice — VIP injections significantly reduced radiation-induced intestinal damage after abdominal irradiation with 12 Gy.

Why it matters

Radiation damage to the gut is a serious side effect of cancer treatment, with limited options for protection or repair. This study shows that VIP — a natural peptide already present in the gut's nervous system — can protect intestinal stem cells and accelerate gut repair after radiation. This could lead to new supportive treatments for cancer patients undergoing abdominal radiation therapy.

The numbers in context

6 Gy irradiation (organoids) · 12 Gy abdominal irradiation (mice) · p38 MAPK pathway · Lgr5+ progenitor cells

How the study worked

Researchers grew intestinal organoids (miniature gut structures) from mouse jejunal tissue and treated them with VIP before and after 6 Gy irradiation. They used Lgr5-reporter mice to track intestinal stem cells and their proliferation. For in vivo validation, mice received 12 Gy abdominal irradiation followed by intraperitoneal VIP injections. Analysis included epithelial differentiation markers, stem cell number and activity, and tissue damage assessment.

Who was studied

C57BL/6J mice and Lgr5-reporter mice (male and female), with jejunal organoid cultures

What this study cannot tell us

This is an animal study using mice — results need to be validated in humans. The organoid model, while informative, does not fully replicate the complexity of the intact human gut environment including immune cells, blood supply, and the microbiome. The radiation doses and VIP administration protocols would need optimization for clinical translation. Long-term effects of VIP treatment on gut tissue were not assessed.

How to read the evidence

This is a preliminary animal study combining in vitro organoid experiments with in vivo mouse validation. While the consistency across both models strengthens the findings, translation to human radiation injury patients requires clinical trials.

When this study was published

Published in 2024, this is a very recent study reflecting current advances in understanding how neuropeptides regulate intestinal stem cell biology and tissue regeneration.

The bigger picture

Radiation enteritis — gut damage from cancer radiation — affects thousands of patients and has few effective treatments. This study reveals that the gut's own nervous system produces a peptide (VIP) that can drive intestinal repair. This connects to the growing understanding that the enteric nervous system actively controls gut regeneration, and suggests that neuropeptide-based therapies could become a new approach to protecting the gut during cancer treatment.

Questions still open

Could VIP be administered to cancer patients before or during radiation therapy to prevent gut damage?
Does VIP's promotion of cell proliferation carry any risk of promoting tumor growth in the irradiated area?
Would VIP also protect the gut from chemotherapy-induced damage, which shares some mechanisms with radiation injury?

Common questions

What is VIP and what does it normally do in the gut?

Vasoactive intestinal peptide (VIP) is a natural molecule produced by nerves running through your intestinal wall. It normally helps control gut movement, blood flow to the intestinal lining, fluid secretion, and immune cell activity. This study adds a new role: VIP also regulates intestinal stem cells that repair and regenerate the gut lining.

How could VIP help cancer patients getting radiation treatment?

Radiation therapy often damages the gut lining, causing painful side effects like diarrhea, nausea, and inflammation. This study showed that VIP injections significantly reduced gut damage in irradiated mice by boosting the regeneration of intestinal stem cells. If these results hold in humans, VIP could become a protective treatment given alongside radiation to minimize gut side effects.

Read the original research

Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury.

Stem cell research & therapy, 15(1), 348

View on PubMed ↗Publisher’s paper ↗

Citation

Agibalova, Tatiana; Hempel, Anneke; Maurer, H Carlo; Ragab, Mohab; Ermolova, Anastasia; Wieland, Jessica; Waldherr Ávila de Melo, Caroline; Heindl, Fabian; Giller, Maximilian; Fischer, Julius Clemens; Tschurtschenthaler, Markus; Kohnke-Ertel, Birgit; Öllinger, Rupert; Steiger, Katja; Demir, Ihsan Ekin; Saur, Dieter; Quante, Michael; Schmid, Roland M; Middelhoff, Moritz. (2024). Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury.. Stem cell research & therapy, 15(1), 348. https://doi.org/10.1186/s13287-024-03958-z